NCT07631637尚未招募2 期
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 150
研究概览
简要总结
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH.
In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver injury, and liver scarring. The study will compare ALN-CIDEB with placebo to understand how well ALN-CIDEB works to lower the amount of fat in the liver.
The study is looking at:
- What side effects ALN-CIDEB might cause
- How well ALN-CIDEB works to change liver fat, liver injury, and liver scarring
- How the body and the liver change after having ALN-CIDEB, which can help researchers understand why ALN-CIDEB works better for some people than others
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of MASH documented in the participant's medical history, or a clinical suspicion of MASH based on non-invasive biomarkers and clinical risk factors, including having a history of 1 or more elements of metabolic syndrome as described in the protocol
- •Screening percutaneous liver biopsy demonstrating a NAFLD Activity Score (NAS) ≥4 and fibrosis stage F2 or F3 as described in the protocol
- •Has a FibroScan Aspartate aminotransferase (FAST) score >0.35 either at Screening Visit 1 or within approximately 3 months of Screening Visit 1 as described in the protocol
排除标准
- •Known chronic liver disease other than Metabolic dysfunction-Associated steatotic Liver Disease (MASLD), as determined by the investigator as described in the protocol
- •Prior or current suspected or known drug-induced liver injury within approximately 1 year prior to Screening Visit 1
- •History of liver transplantation, current placement on a liver transplant list, or MELD score >12
- •Known history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion and/or a score on the AUDIT questionnaire ≥8
- •Prior current, or planned future use of a Glucagon-Like Peptide-1 (GLP-1) receptor agonist-based therapy or any medication approved for the treatment of MASH unless used at a generally stable dose and regimen since at least 3 months prior to Screening Visit 1 or the qualifying historical liver biopsy and throughout the screening period with no change to the dose or regimen anticipated during the treatment period as described in the protocol
- •NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
研究者
相似试验
招募中
2 期
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney DiseaseNCT07271186Regeneron Pharmaceuticals195
招募中
2 期
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07527910Regeneron Pharmaceuticals204
招募中
1 期
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsHealthy VolunteerNCT07526116Regeneron Pharmaceuticals88
撤回
3 期
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaCommunity-Acquired Pneumonia (CAP)Acute Respiratory Distress Syndrome (ARDS)LymphopeniaImmunoparalysisSepsisNCT07492875ImmunityBio, Inc.10
招募中
1 期
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisHealthy VolunteerAtopic DermatitisNCT07527923Regeneron Pharmaceuticals144